Hepatic Disease Treatment Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

The hepatic disease treatment market was valued at USD 24.78 Billion in 2024, driven by the rising prevalence of liver diseases across the 8 major markets. It is further expected to grow at a CAGR of about 6.20% in the forecast period of 2025-2034 to reach a value of around USD 45.22 Billion by 2034.

Hepatic Disease Treatment Market Overview

Hepatic disease refers to various disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems.

The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. The high burden of liver disease is propelling the demand for the hepatic disease treatment market. One of the primary factors augmenting the market growth is the increasing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Moreover, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably influencing the market growth.

Further, increasing research and development activities, significant growth in the healthcare industry, and implementation of various government initiatives in order to promote public health are creating a positive outlook for the hepatic disease treatment market value. For instance, the Indian government announced the integration of non-alcoholic fatty liver disease (NAFLD) with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD. Additionally, the development of novel therapeutics and advancements in diagnostic techniques are some of the factors aiding the market expansion.

Hepatic Disease Treatment Market Growth Drivers

Increasing Prevalence of Liver Diseases to Affect the Market Landscape Significantly

Recent studies reveal that liver disease is responsible for 2 million deaths every year and accounts for 4% of all deaths worldwide (1 in every 25 deaths). It is reported that roughly two-thirds of all liver-related deaths occur in males. Liver cancer also poses a significant health challenge, causing 600,000 to 900,000 deaths annually, primarily as a result of cirrhosis and hepatocellular carcinoma . According to the American Cancer Society, the year 2024 will witness the diagnosis of around 41,630 individuals with primary liver cancer and intrahepatic bile duct cancer in the United States. Further, it is also estimated that 29,840 individuals will die from these cancers, indicating the need for effective medications to combat this liver disease. Thus, the rising burden of liver diseases is set to bolster the growth and innovation in the market.

Hepatic Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Advancements in Diagnostic Technologies

One of the major market trends is the rising improvements in diagnostic technologies such as imaging techniques (MRI, CT scans) and biomarker-based tests. These advancements help in the early and accurate diagnosis of liver diseases.

Increased Investment in R&D

Increased funding and grants for research and development of hepatic disease treatments by the government and healthcare organizations is a major market trend. This investment is expected to accelerate the discovery and commercialization of new and effective therapies, which is anticipated to boost the hepatic disease treatment market value.

Growing Regulatory Support

The market benefits from the presence of a favorable regulatory environment, with regulatory bodies offering orphan drug designations and incentives for novel therapies that are designed to treat rare liver diseases. In addition, the implementation of fast-track and accelerated approval processes is anticipated to support market expansion in the forecast period.

Heightened Public Awareness

The market is witnessing heightened public awareness regarding liver diseases and their treatments which is prompting more individuals to seek medical attention. This trend is supported by rising public health campaigns and education programs aimed at highlighting the importance of early intervention and adherence to treatment protocols.

Hepatic Disease Treatment Market Segmentation

Hepatic Disease Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type

• Antiviral Drugs
• Monoclonal Antibodies
• Immunosuppressants Drugs
• Vaccines
• Corticosteroids Drugs
• Targeted Therapy
• Others

Market Breakup by Disease Type

• Hepatitis
• Non-Alcoholic Fatty Liver Disease (NAFLD)
• Hepatic Cancer
• Other

Market Breakup by Route of Administration

• Parenteral
• Oral
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Hepatic Disease Treatment Market Share

The Antiviral Drugs Segment Based on Treatment Type is Anticipated to Witness Substantial Growth

Based on the treatment type, the market is segmented into antiviral drugs, monoclonal antibodies, immunosuppressant drugs, vaccines, corticosteroid drugs, targeted therapy, and others. The antiviral drugs segment holds a high market value which can be attributed to the high prevalence of viral hepatitis such as hepatitis B and C which can result in chronic liver diseases, cirrhosis, and liver cancer. The chronic nature of these hepatic diseases drives the need for long-term antiviral treatment.

Hepatic Disease Treatment Market Analysis by Region

The United States represents a major market for hepatic disease treatment owing to the high prevalence of liver diseases including hepatitis B and C. According to the Centers for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year. The increasing number of cases of such liver diseases propels the demand for effective treatments and therapeutics in the region. India is also projected to have substantial market growth in the forecast period owing to improvements in healthcare infrastructure, rising spending on healthcare services, and increased government funds and grants for research and development of hepatic disease treatments.

Leading Players in the Hepatic Disease Treatment Market

The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AbbVie Inc

American pharmaceutical company AbbVie is a major market player and invests heavily in R&D to develop innovative therapies for hepatic diseases. The company is known for its combination therapies to treat chronic hepatitis C virus (HCV) infection such as its FDA-approved combination drug MAVYRET (glecaprevir/pibrentasvir).

Merck & Co., Inc

United States-based Merck & Co., focuses on developing novel treatments for liver diseases, including both antivirals and vaccines. The company is also involved in health initiatives aimed at eliminating hepatitis.

F. Hoffmann-La Roche Ltd

Swiss multinational holding healthcare company Roche is engaged in advancing its pipeline of hepatic disease treatments. Its drug Pegasys (peginterferon alfa-2a) is often used in combination with other antiviral medications to treat chronic hepatitis B and C infections.

Eli Lilly and Company

Headquartered in Indiana (United States), pharmaceutical giant Eli Lilly and Company is one of the key players in the market. It is focused on developing treatments that target liver cancer and fibrosis.

Key Questions Answered in the Hepatic Disease Treatment Market Report

• What was the hepatic disease treatment market value in 2024?
• What is the hepatic disease treatment market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on the treatment type?
• What is the market breakup based on the disease type?
• What is the market breakup by route of administration?
• What are the major factors aiding the hepatic disease treatment market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of hepatic diseases affect the market landscape?
• What are the major hepatic disease treatment market trends?
• How does the rise in the geriatric population impact the market size?
• Which treatment type will dominate the market share?
• Which disease type is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Who are the key players involved in the hepatic disease treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.